Aspheric IOLs perform better than spherical IOLs

Article

Aspheric intraocular lenses induce less wavefront aberrations and perform better in photopic and mesopic conditions than spherical IOLs.

Aspheric intraocular lenses (IOLs) induce less wavefront aberrations and perform better in photopic and mesopic conditions than spherical IOLs, according to a report published in the September issue of Journal of Refractive Surgery.

Aldo Caporossi and co-workers from the University of Siena, Italy conducted a prospective, comparative, randomized study of 250 eyes of 125 subjects with bilateral cataracts. Patients were randomly assigned to receive either a spherical biconvex optic (AcrySof SN60AT [Alcon] or Sensar AR40e [AMO]) or an aspheric optic (AcrySof IQ SN60WF [Alcon], Tecnis Z9000 [AMO] or SofPort L161AO [Bausch & Lomb]).

Aspheric IOLs demonstrated better contract sensitivity compared with spherical IOLs at spatial frequencies of six, 12 and 18 cycles per degree under photopic conditions and at all spatial frequencies under mesopic conditions. There were no significant differences between the aspheric IOLs at all spatial frequencies under either photopic or mesopic conditions. Mean total spherical aberration was statistically lower in dominant eyes with aspheric IOLs compared with eyes with spherical IOLs for a 5 mm pupil diameter.

The results of this comparative study confirm that it is possible to improve the optical performance of IOLs by modifying the surfaces.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.